With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.

中文翻译：

---

SARS-CoV-2 对 181 名囊性纤维化患者的全球影响

随着 SARS-CoV-2 大流行的蔓延，我们需要更好地了解其对特定患者群体（如囊性纤维化 (CF)）的影响。我们报告了 2020 年 6 月 13 日之前被诊断出患有 SARS-CoV-2 的 19 个国家的 181 名 CF 患者（移植后 32 名）。 SARS-CoV-2 感染似乎表现出与一般情况相似的结果11 人接受重症监护（移植后 7 人），死亡 7 人（移植后 3 人）。更严重的临床病程可能与年龄较大、CF 相关的糖尿病、感染前一年肺功能降低以及接受器官移植有关。虽然这个大型队列的结果总体上比最初担心的要好，可能是由于与其他慢性病相比，CF 人群相对年轻的保护作用，